Zealand Pharma A/S Appoints Eric Rojas As Vice President Of Investor Relations, Effective April 15, 2026

Zealand Pharma A/S, a biotechnology company focused on advancing metabolic health, has announced the appointment of Eric Rojas as Vice President of Investor Relations, effective April 15, 2026. In this role, he will report to Chief Financial Officer Henriette Wennicke and will be based in Massachusetts, United States.

Eric Rojas brings over twenty years of experience in investor relations and finance, with a strong track record of supporting both U.S.-listed and European-listed biotechnology and pharmaceutical companies. His background includes senior positions at leading organizations such as Vertex Pharmaceuticals, Stoke Therapeutics, and Shire, which was later acquired by Takeda Pharmaceutical Company in a $62 billion transaction.

Henriette Wennicke, Executive Vice President and Chief Financial Officer of Zealand Pharma, expressed confidence in the appointment, noting that Eric’s deep understanding of capital markets and his well-established relationships within the investment community will play an important role as the company continues to grow. She highlighted that Zealand Pharma is entering a significant phase in its development, with multiple upcoming milestones and opportunities that position it as a next-generation biotechnology company.

Commenting on his new role, Eric Rojas said that Zealand Pharma is at an important stage in its evolution, supported by a differentiated pipeline, strong partnerships, and meaningful upcoming data readouts. He also pointed to the company’s expansion in the United States, including the establishment of a new research site in Cambridge, Massachusetts, as a key moment of growth. He added that he looks forward to engaging with the investment community to ensure that the company’s progress and scientific advancements are clearly communicated and well understood.

This appointment reflects Zealand Pharma’s continued focus on strengthening its leadership team as it advances its strategic priorities and prepares for a period of increased activity across its development pipeline and global operations.